Therefore, the purpose of this study was to evaluate the economics of osimertinib versus first-generation EGFR-TKI (gefitinib or erlotinib) as the first-line treatment of untreated EGFR mutation-positive advanced NSCLC based on the FLAURA trial results from the perspective of the Chinese healthcare system, in order to provide reference for clinical treatment option and medical decision-making in China. This evidence concerns the gene EGFR and non-small cell lung carcinoma.